1 January 2014
| Anna E Wright, Jerry Raju, Nick Rukin
|
Urologic Oncology
Case 1 1. What does this sagittal magnetic resonance imaging (MRI) scan show? 2. Which cancers commonly cause this? 3. What is the acute management? Case 2 1. What is the diagnosis? 2. What local effects can this mass cause?...
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I promised to tell you about removing kidneys, by...
1 November 2015
| Sarah Sharp, Jane Belfield
|
Uroradiology
The purpose of this article is to explain and illustrate common renal vascular variants that can be depicted with imaging. Renal vessels commonly present a wide range of variations [1]; before major renal or vascular surgery is undertaken, accurate portrayal...
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You may feel somewhat distanced from the medical practitioners of mediaeval Florence but...
9 March 2020
| Jonathan Charles Goddard
|
Andrology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). If I were to say to you, ‘The Blue Pill’ I suspect you...
1 November 2017
| Styliani Germanou, Sophie Merrick, Simon Chowdhury
|
Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...
Background Pelviureteric junction obstruction (PUJO) is defined as a functionally significant impairment of urine flow from the renal pelvis into the proximal ureter. For more than a century, surgery was considered the first-choice approach to management. However, the widespread use...
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...
COVID-19 had a major impact on our hospital services from early in the pandemic, with almost three times as many patients being ventilated compared to the normal ITU capacity at the beginning of April. During the build-up to this point,...
The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...
3 September 2021
| Hannah Warren, Ben Challacombe
|
Urologic Oncology
Active surveillance for prostate cancer: missing the boat Case In 2005 a 43-year-old man of Afro-Caribbean ethnicity was referred to our centre for investigation of suspected prostate cancer. Digital rectal exam revealed a firm right lobe, PSA of 2.3ng/ml, prostate...
8 November 2021
| Conor Devlin, Marcelino Yazbek Hanna
|
Urologic Oncology
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...